Eli Lilly’s semaglutide achieves 28.7% weight loss in groundbreaking trial
Eli Lilly’s experimental drug, semaglutide, has shown remarkable results in a Phase 3 trial. Participants achieved an average weight loss of 28.7 percent, outperforming the company’s previous top drug, Zepbound. The findings also revealed unexpected benefits for joint pain in patients with knee osteoarthritis.
Semaglutide works by activating three hormone receptors at once: GLP-1, GIP, and glucagon. This triple-action approach sets it apart from other weight-loss medications. In the trial, it not only reduced body weight but also eased joint pain significantly.
Semaglutide’s strong performance in weight loss and pain reduction highlights its promise as a future therapy. With more trial data due in 2026, the drug may redefine treatment options for obesity and joint conditions. Competitors like Novo Nordisk are now racing to match its potential impact.
